Connection

Hermes Florez to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications Hermes Florez has written about Cost-Benefit Analysis.
Hermes Florez
Connection Strength
0.108
Cost-Benefit Analysis
  1. A new angle for glp-1 receptor agonist: the medical economics argument. Editorial on: Huetson P, Palmer JL, Levorsen A, et al. Cost-effectiveness of the once-daily glp-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway. J Med Econ 2015: 1-13 [Epub ahead of print]. J Med Econ. 2015; 18(12):1029-31.
    View in: PubMed
    Score: 0.108
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.